Well I guess that's that. Focus 100% on core profitable business, ceasing the flow of cash to Medivet and leaving the potential for a $2m payday depending on criteria set.
Not seeing the accounts/ Medivet business in full I'm guessing this suggests there is a significant cash injection (larger than first thought) needed just to continue business activities? On the positive side MLA management would know Delk well and know who they are selling to and hopefully getting a reasonably balanced deal in return.
Interestingly, where does that leave MLA now? Previously earnings figures of approx 1mill have been thrown around (proof of these in ongoing quarterlies will now be needed) however, with a market cap of approx 7mill, there is potential there. if a bit of cash can be banked further 'complementary' acquisitions to the MLA product line could likely be expected
all DYOR, IMO etc....
MLA Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
